Table 3.
Amino acid changes or mutations in the pmrCAB polymyxin B-resistant WT-derived strains (compared to their parental WT strain ATCC 17978) and pmrCAB variants of polymyxin B-resistant clinical isolates (compared to a consensus sequence)a
Strain | PXBb MIC (μg/ml) | Amino acid change(s) inc: |
|||||||
---|---|---|---|---|---|---|---|---|---|
pmrC (549 aa) |
pmrA (224 aa) |
pmrB (444 aa) |
|||||||
aa 1–236 | Sulfatase (aa 237–532) | Rec (aa 5–116) | aa 117–131 | aa 1–215 | HisK (aa 216–276) | aa 277–330 | HATPaseC (aa 331–419) | ||
WT | 0.5 | ||||||||
R9 | 2 | R231L | |||||||
R3 | 4 | G315D | |||||||
R5 | 4 | M12I | |||||||
R6 | 4 | R263P | Q277H | ||||||
R7 | 4 | G315D | |||||||
R2 | 8 | T235I | |||||||
C14 | 8 | T7I, A211V | Δ160 | ||||||
C2 | 16 | D64V, L208F | |||||||
C8 | 16 | L208F | |||||||
C11 | 16 | H499R* | Δ32–35 | P360Q* | |||||
C13 | 16 | P170Q | |||||||
C12 | 16 | N256I | |||||||
C87 | 16 | F90L | S119T | P233S | P360Q* | ||||
C5 | 32 | R263C | P377L | ||||||
C4 | 64 | A226V | |||||||
C15 | 64 | A80V, P170L |
Sequences were compared to a consensus sequence made by alignment of the pmrCAB operons from the genome sequences of the following strains: ATCC 17978 (Yale University); AYE (Genoscope, France); ACICU (National Research Centre, Italy); AB0057, AB307-0294, and AB900 (Case Western Reserve University); 1656-2 (Kyungpook National University/GenoTech Corporate, South Korea), and TCDC-AB0715 (Taiwan Center for Disease Control, Taiwan). Accordingly, the identified single nucleotide polymorphisms (SNPs; naturally variant between the sequenced isolates) pmrC(F166L), pmrC(A370S), pmrC(K531T), and pmrB(A444V) occurred in each of the clinical isolates C2, C4, C5, C8, C12, C13, and C15 but not in C11, C14, or C87. In addition, the SNP pmrC(H499R) (marked with an asterisk) was found only in clinical isolate C11. The SNP pmrB(P360Q) (marked with an asterisk) occurred in clinical isolates C11 and C87 but none of the other strains. aa, amino acids.
Polymyxin B (PXB) MICs were assessed by the broth microdilution method according to the CLSI.
The predicted domains according to the NCBI domain predictor (www.ncbi.nlm.nhi.gov/protein) are indicated as follows: sulfatase, sulfatase domain; Rec, signal receiver domain; HisK, histidine kinase (dimerization/phosphoacceptor) domain; and HATPaseC, histidine-kinase-like ATPase. Only domains or regions displaying mutations or variants are shown. The amino acid (aa) positions corresponding to these domains are displayed in brackets.